Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843945 · ClinicalTrials.gov registry record · Phase 1
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
A Phase 1 study of Pancreatic Cancer, sponsored by CivaTech Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 6
- Study locations
NCT02843945 is a Phase 1 study of Pancreatic Cancer that is actively recruiting participants, run by CivaTech Oncology. The registered enrollment target is 80 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (80% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT02843945, a Phase 1 study of Pancreatic Cancer, is actively recruiting participants, sponsored by CivaTech Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 6
- Study locations
Study Summary
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Conditions Studied
Interventions
- DEVICE Directional Brachytherapy Source Implant
Study Locations (6)
Illinois
- Rush University Cancer Center - Chicago
- Advocate Christ Medical Center - Oak Lawn
Florida
- Tampa General Hospital - Tampa
Louisiana
- University Medical Center LSU - New Orleans
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Virginia
- Virginia Commonwealth University Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02843945
The ClinicalTrials.gov registry entry for NCT02843945 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (80% lower). The listed sponsor is CivaTech Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Directional Brachytherapy Source Implant is the first listed.
NCT02843945 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT02843945 about?
NCT02843945 is a clinical study titled "Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source". Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
What is the current status of trial NCT02843945?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2017-05-31. Estimated completion is 2028-10-30.
What conditions does trial NCT02843945 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT02843945?
The interventions under investigation include: Directional Brachytherapy Source Implant (DEVICE).
Who is sponsoring clinical trial NCT02843945?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02843945 being conducted?
This trial has 6 study locations across Florida, Illinois, Louisiana, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.